Understanding Human Microbiota Offers Novel and Promising Therapeutic Options against Candida Infections

• Published in: Pathogens (Basel) Vol. 10; no. 2; p. 183
• Main Authors: Hameed, Saif, Hans, Sandeep, Monasky, Ross, Thangamani, Shankar, Fatima, Zeeshan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 09.02.2021; MDPI AG
• Subjects: Candida; gastrointestinal; gut; microbiota; nasopharyngeal; oral; Review; gastrointestinal; microbiota; metabolite; Candida; gut; oral; nasopharyngeal; vaginal
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens10020183

Human fungal pathogens particularly of species are one of the major causes of hospital acquired infections in immunocompromised patients. The limited arsenal of antifungal drugs to treat infections with concomitant evolution of multidrug resistant strains further complicates the management of these infections. Therefore, deployment of novel strategies to surmount the infections requires immediate attention. The human body is a dynamic ecosystem having microbiota usually involving symbionts that benefit from the host, but in turn may act as commensal organisms or affect positively (mutualism) or negatively (pathogenic) the physiology and nourishment of the host. The composition of human microbiota has garnered a lot of recent attention, and despite the common occurrence of spp. within the microbiota, there is still an incomplete picture of relationships between spp. and other microorganism, as well as how such associations are governed. These relationships could be important to have a more holistic understanding of the human microbiota and its connection to infections. Understanding the mechanisms behind commensalism and pathogenesis is vital for the development of efficient therapeutic strategies for these infections. The concept of host-microbiota crosstalk plays critical roles in human health and microbiota dysbiosis and is responsible for various pathologies. Through this review, we attempted to analyze the types of human microbiota and provide an update on the current understanding in the context of health and infections. The information in this article will help as a resource for development of targeted microbial therapies such as pre-/pro-biotics and microbiota transplant that has gained advantage in recent times over antibiotics and established as novel therapeutic strategy.